JESSICA WEEKS JUBER: Open Payments
NPI 1184981938 · TOOELE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,048 in 57 payments from 18 companies in 2025. Trend: 2023 $1,053 · 2024 $974 · 2025 $1,048
Food & beverage: $1,048
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $354 |
| Otsuka America Pharmaceutical, Inc. | 6 | $108 |
| Alkermes, Inc. | 4 | $93 |
| Lilly USA, LLC | 4 | $71 |
| Indivior Inc. | 3 | $67 |
| Novo Nordisk Inc | 3 | $54 |
| MERZ NORTH AMERICA, INC. | 1 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Corium, LLC | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
Products named: VRAYLAR, REXULTI, ARISTADA, MOUNJARO, SUBLOCADE, Xeomin, QULIPTA, Wegovy.
Industry payments across UT — which companies pay providers there.
